Abstract
[No abstract]
| Original language | English |
|---|---|
| Article number | q6 |
| Number of pages | 8 |
| Journal | BMJ |
| Volume | 384 |
| DOIs | |
| Publication status | Published - 11 Jan 2024 |
Bibliographical note
Funding Information:Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: AH is doing a PhD funded by the Medical Research Council (grants MR/W006308/1 and MR/X018636/1), is co-chair of the Faculty of Public Health Drugs Special Interest Group, volunteers for the Loop (a drug checking organisation), is a member of the Drug Science Enhanced Harm Reduction Working Group, and has worked on various projects advocating for the decriminalisation of drug possession and harm reduction interventions; TDB is employed as a salaried medical resident (trainee) by Nova Scotia Health and Dalhousie University, holds a grant from the Canadian Institutes of Health Research (FRN 185469) focused on injection drug use associated infective endocarditis, and practices addiction medicine and prescribes safer supply medications, but does not receive any financial benefit from doing so; MS is project executive for the European Network of People who Use Drugs (EuroNPUD); EuroNPUD has received unrestricted educational grants from Camurus and Indivior to deliver a client resource on opioid agonist maintenance treatment and to run an advocacy event at the United Nations Commission on Narcotic Drugs in March 2023, respectively; EuroNPUD has also received a grant from ViiV Europe, the donor arm of the HIV pharmaceutical company.
Research Groups and Themes
- TARG
- TARG-otherdrugs